Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kusuri No Aoki Holdings Co., Ltd. (3549.T)
JPY3,779.00
+34.00 (+0.91%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
No. 1 block, 4 blocks, Yokoemachi 924-8510
Hakusan, JP
Hakusan, JP
CEO
Hironori Aoki
Website
kusuri-aoki-hd.co.jp
IPO
2006-02-17
ISIN JP3266190002
Description
Founded in 1999 and headquartered in Hakusan, Japan, Kusuri No Aoki Holdings Co., Ltd. primarily engages in the sale and dispensing of medications, cosmetics, and various everyday consumer products across Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY3,779.00
+34.00 (+0.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
253.8K
Beta
0.02
Float Shares
21.02M
Free Float %
22.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.12% | -4.54% | -7.69% | -14.69% | -11.28% | -23.47% | -1.92% | +47.74% | +35.43% | +61.51% | +2,829.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,779.00
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.95
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+13.0% ★ Q2'26: +11.2% (vs Q2'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+1.5% Q2'26: -49.4% (vs Q2'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+4.0% ★ Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.8% Q2'26: +3.9% (vs Q2'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+8.3% ★ Q2'26: +7.0% (vs Q2'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-5.1% ★ Q2'26: -9.9% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×3.49× Q2'26: 3.76× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
May 2015 actual |
May 2016 actual |
May 2017 actual |
May 2018 actual |
May 2019 actual |
May 2020 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 5 Rev. Ana. 5 EPS Ana. |
May 2027 5 Rev. Ana. 5 EPS Ana. |
May 2028 4 Rev. Ana. 4 EPS Ana. |
May 2029 1 Rev. Ana. 1 EPS Ana. |
May 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
134.99B
est: 134.20B (+0.6%)
|
163.46B
est: 162.27B (+0.7%)
|
188.74B
est: 190.43B (-0.9%)
|
221.29B
est: 221.20B (+0.0%)
|
250.89B
est: 252.88B (-0.8%)
|
300.17B
est: 298.92B (+0.4%)
|
305.88B
est: 303.30B (+0.9%)
|
328.34B
est: 332.75B (-1.3%)
|
378.87B
est: 378.86B (+0.0%)
|
436.88B
est: 449.77B (-2.9%)
|
501.47B
est: 498.74B (+0.5%)
|
566.47B
561.20B – 569.00B
+13.6% YoY
|
635.54B
611.47B – 649.70B
+12.2% YoY
|
696.48B
670.10B – 712.00B
+9.6% YoY
|
753.50B
753.50B – 753.50B
+8.2% YoY
|
806.14B
775.61B – 824.10B
+7.0% YoY
|
| EBITDA |
10.40B
est: 10.13B (+2.7%)
|
12.46B
est: 12.25B (+1.8%)
|
15.13B
est: 14.37B (+5.2%)
|
17.15B
est: 16.70B (+2.7%)
|
19.69B
est: 19.09B (+3.1%)
|
22.63B
est: 22.56B (+0.3%)
|
24.10B
est: 22.89B (+5.3%)
|
23.76B
est: 25.12B (-5.4%)
|
28.74B
est: 28.60B (+0.5%)
|
32.00B
est: 35.99B (-11.1%)
|
39.18B
est: 39.91B (-1.8%)
|
45.33B
44.91B – 45.53B
+13.6% YoY
|
50.85B
48.93B – 51.99B
+12.2% YoY
|
55.73B
53.62B – 56.97B
+9.6% YoY
|
60.29B
60.29B – 60.29B
+8.2% YoY
|
64.51B
62.06B – 65.94B
+7.0% YoY
|
| EBIT |
7.78B
est: 6.46B (+20.4%)
|
9.04B
est: 7.81B (+15.7%)
|
10.85B
est: 9.16B (+18.4%)
|
12.26B
est: 10.64B (+15.1%)
|
14.15B
est: 12.17B (+16.3%)
|
16.36B
est: 14.38B (+13.7%)
|
16.62B
est: 14.59B (+13.9%)
|
14.75B
est: 16.01B (-7.9%)
|
17.03B
est: 18.23B (-6.6%)
|
19.93B
est: 24.32B (-18.0%)
|
25.97B
est: 26.96B (-3.7%)
|
30.63B
30.34B – 30.76B
+13.6% YoY
|
34.36B
33.06B – 35.13B
+12.2% YoY
|
37.66B
36.23B – 38.49B
+9.6% YoY
|
40.74B
40.74B – 40.74B
+8.2% YoY
|
43.58B
41.93B – 44.56B
+7.0% YoY
|
| Net Income |
5.21B
est: 5.22B (-0.2%)
|
6.50B
est: 7.10B (-8.4%)
|
8.18B
est: 7.98B (+2.5%)
|
8.82B
est: 9.17B (-3.7%)
|
10.65B
est: 10.85B (-1.8%)
|
12.42B
est: 11.71B (+6.0%)
|
12.06B
est: 12.72B (-5.2%)
|
9.84B
est: 11.36B (-13.4%)
|
12.33B
est: 14.68B (-16.0%)
|
12.31B
est: 12.77B (-3.6%)
|
17.79B
est: 17.57B (+1.2%)
|
18.13B
16.39B – 18.88B
+3.2% YoY
|
19.43B
17.80B – 20.94B
+7.2% YoY
|
20.90B
19.54B – 22.98B
+7.6% YoY
|
24.24B
23.28B – 25.20B
+16.0% YoY
|
27.08B
25.75B – 27.87B
+11.7% YoY
|
| SGA |
25.46B
est: 22.04B (+15.5%)
|
28.56B
est: 26.65B (+7.2%)
|
35.54B
est: 31.28B (+13.6%)
|
42.18B
est: 36.34B (+16.1%)
|
48.82B
est: 41.54B (+17.5%)
|
61.48B
est: 49.10B (+25.2%)
|
66.20B
est: 49.82B (+32.9%)
|
66.91B
est: 54.66B (+22.4%)
|
79.35B
est: 62.23B (+27.5%)
|
87.73B
est: 89.20B (-1.7%)
|
93.87B
est: 98.91B (-5.1%)
|
112.34B
111.30B – 112.84B
+13.6% YoY
|
126.04B
121.27B – 128.85B
+12.2% YoY
|
138.13B
132.89B – 141.20B
+9.6% YoY
|
149.43B
149.43B – 149.44B
+8.2% YoY
|
159.87B
153.82B – 163.44B
+7.0% YoY
|
| EPS |
55.46
est: 51.51 (+7.7%)
|
69.03
est: 70.05 (-1.5%)
|
86.74
est: 78.74 (+10.2%)
|
93.41
est: 90.40 (+3.3%)
|
112.62
est: 106.98 (+5.3%)
|
131.26
est: 115.48 (+13.7%)
|
127.51
est: 125.43 (+1.7%)
|
104.01
est: 112.01 (-7.1%)
|
130.30
est: 144.63 (-9.9%)
|
130.10
est: 134.96 (-3.6%)
|
175.42
est: 177.67 (-1.3%)
|
189.29
169.24 – 194.96
+6.5% YoY
|
203.32
183.83 – 216.24
+7.4% YoY
|
223.17
201.77 – 237.35
+9.8% YoY
|
252.90
240.45 – 260.23
+13.3% YoY
|
279.70
265.93 – 287.80
+10.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
20.21B
OE per share TTM
200.07
Owner's Yield
6.14%
Maintenance CapEx ratio
129.23%
Maint CapEx / Avg PPE
33.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 93 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Japan Small-Cap ETF SCJ | 0.06% | 164.5K | 0.50% |
| 2 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.06% | 341.2K | 0.58% |
| 3 | Dimensional - International Vector Equity ETF DXIV | 0.04% | 71.7K | 0.53% |
| 4 | Schwab Fundamental International Small Company Index ETF FNDC | 0.03% | 1.01M | 0.39% |
| 5 | iShares JPX-Nikkei 400 ETF JPXN | 0.03% | 41.2K | 0.48% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 86.7K | 0.30% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.55M | 0.39% |
| 8 | Vanguard International Dividend Appreciation ETF VIGI | 0.03% | 2.33M | 0.07% |
| 9 | Invesco JPX-Nikkei 400 UCITS ETF N400.L | 0.02% | 48.3K | 0.19% |
| 10 | Invesco JPX-Nikkei 400 UCITS ETF N4US.L | 0.02% | 48.4K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.72M
Shares Outstanding
94.96M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hironori Aoki | Chairman of the Board, President & Chief Executive Officer | — | male |
| Hitoshi Iijima | MD & Director | — | male |
| Takanori Aoki | Executive Vice President & Director | — | male |
| Yasutoshi Aoki | Chief Advisor & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3549.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
